Accessibility Statement

Press Releases

Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks

June 8, 2024

Tags |  Product

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine INDIANAPOLIS , June 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a

Lilly announces departure of Anat Ashkenazi, chief financial officer

June 5, 2024

Tags |  Corporate

INDIANAPOLIS , June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I

Melissa Seymour to join Lilly as executive vice president of Global Quality

June 4, 2024

Tags |  Corporate

INDIANAPOLIS , June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024 .

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

June 1, 2024

Tags |  Product

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024

Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases

May 29, 2024

Tags |  Impact

New   $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 29, 2024 /PRNewswire/ -- During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States

Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024

Tags |  Financial

INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 . Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA , will

Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

May 24, 2024

Tags |  Corporate

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history Since 2020, the company has committed more than $18 billion to build, upgrade and acquire facilities in the U.S. and Europe   INDIANAPOLIS , May 24, 2024 /PRNewswire/ -- Eli Lilly and Company

Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024

Tags |  Product

INDIANAPOLIS , May 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio ® (abemaciclib; a CDK4/6 inhibitor), Retevmo ® (selpercatinib; a rearranged during transfection [ RET ] inhibitor), olomorasib (an investigational KRAS G12C inhibitor)

More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure

May 21, 2024

Tags |  Product

Nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission INDIANAPOLIS , May 21, 2024 /PRNewswire/ -- In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

May 16, 2024

Tags |  Product

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS , May 16, 2024